[治疗慢性髓性白血病的铁氨酸激酶抑制剂]
1Hôpital Saint-Louis, service d'hématologie adulte, AP-HP, Paris, France, et France Intergroupe des leucémies myéloïdes chroniques.
La Revue du praticien
|January 31, 2024
概括
氨酸激酶抑制剂 (TKIs) 已经将慢性髓性白血病 (CML) 从致命转变为慢性. 需要进一步的研究来克服抗药性等挑战,并实现治愈.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 伊马替尼的发现,一个BCR::ABL1氨酸激酶抑制剂 (TKI),彻底改变了慢性髓性白血病 (CML) 治疗.
- 通过TKIs,CML从致命疾病转变为可管理的慢性疾病,显著改善了患者的治疗结果.
研究的目的:
- 审查技术知识在CML管理中的影响.
- 突出目前的治疗目标和CML治疗中的剩余挑战.
主要方法:
- 对伊马替尼布和随后的TKI批准的审查.
- 对治疗目标和患者结果的分析.
- 确定CML正在进行的研究需求.
主要成果:
- 伊马替尼和五种额外的TKI已经获得批准,使得个性化治疗成为可能.
- 终身TKI治疗旨在预防爆炸危机并延长预期寿命.
- 在少数患者中,可以实现无治疗缓解.
结论:
- 通过TKI,CML的预后得到了显著的改善,预期寿命接近正常.
- 仍然存在挑战,包括改进评分系统,提高TKI安全性,克服耐药性,并找到治疗CML的方法.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
167
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Receptor Tyrosine Kinases
12.9K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.9K


